Abstract
Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.
Original language | English |
---|---|
Pages (from-to) | 7084-7085 |
Number of pages | 2 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 59 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2015 |